A New Reversible and Potent P2Y12 Receptor Antagonist (ACT-246475): Tolerability, Pharmacokinetics, and Pharmacodynamics in a First-in-Man Trial

被引：0
|
作者：
Daniela Baldoni
Shirin Bruderer
Andreas Krause
Marcello Gutierrez
Pierre Gueret
Béatrice Astruc
Jasper Dingemanse
机构：
[1] Actelion Pharmaceuticals Ltd,Department of Clinical Pharmacology
[2] University Hospital Pontchaillou,Hemostasis Unit
[3] Biotrial,undefined
来源：
Clinical Drug Investigation | 2014年 / 34卷
关键词：
Dose Group; Prasugrel; Ticagrelor; Dichlorvos; P2Y12 Reaction Unit;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：807 / 818
页数：11
相关论文
共 14 条
  • [1] The reversible P2Y12 antagonist ACT-246475 causes significantly less blood loss than ticagrelor at equivalent antithrombotic efficacy in rat
    Rey, Markus
    Kramberg, Markus
    Hess, Patrick
    Morrison, Keith
    Ernst, Roland
    Haag, Franck
    Weber, Edgar
    Clozel, Martine
    Baumann, Martine
    Caroff, Eva
    Hubler, Francis
    Riederer, Markus A.
    Steiner, Beat
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2017, 5 (05):
  • [2] Evaluation of Tolerability, Pharmacokinetics and Pharmacodynamics of Vicagrel, a Novel P2Y12 Antagonist, in Healthy Chinese Volunteers
    Li, Xiaojiao
    Liu, Cai
    Zhu, Xiaoxue
    Wei, Haijing
    Zhang, Hong
    Chen, Hong
    Chen, Guiling
    Yang, Deming
    Sun, Hongbin
    Shen, Zhenwei
    Zhang, Yifan
    Li, Wei
    Yang, Jin
    Liu, Yongqiang
    Lai, Xiaojuan
    Gong, Yanchun
    Liu, Xuefang
    Li, Yongguo
    Zhong, Dafang
    Niu, Junqi
    Liu, Bin
    Ding, Yanhua
    FRONTIERS IN PHARMACOLOGY, 2018, 9
  • [3] Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects
    Teng, Renli
    Butler, Kathleen
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 66 (05) : 487 - 496
  • [4] Efficacy and Safety of Ticagrelor: A Reversible P2Y12 Receptor Antagonist
    Anderson, Shawn D.
    Shah, Niren K.
    Yim, Juwon
    Epstein, Benjamin J.
    ANNALS OF PHARMACOTHERAPY, 2010, 44 (03) : 524 - 537
  • [5] Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects
    Renli Teng
    Kathleen Butler
    European Journal of Clinical Pharmacology, 2010, 66 : 487 - 496
  • [6] Ticagrelor: The First Reversibly Binding Oral P2Y12 Receptor Antagonist
    Husted, Steen
    van Giezen, J. J. J.
    CARDIOVASCULAR THERAPEUTICS, 2009, 27 (04) : 259 - 274
  • [7] Ticagrelor: Oral Reversible P2Y12 Receptor Antagonist for the Management of Acute Coronary Syndromes
    Cheng, Judy W. M.
    CLINICAL THERAPEUTICS, 2012, 34 (06) : 1209 - 1220
  • [8] Platelet P2Y12 receptor antagonist pharmacokinetics and pharmacodynamics: A foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies
    Becker, Richard C.
    Gurbel, Paul A.
    THROMBOSIS AND HAEMOSTASIS, 2010, 103 (03) : 535 - 544
  • [9] Identification of a New Morpholine Scaffold as a P2Y12 Receptor Antagonist
    Ahn, Young Ha
    Lee, Joo-Youn
    Park, Hee Dong
    Kim, Tae Hun
    Park, Min Chul
    Choi, Gildon
    Kim, Sunghoon
    MOLECULES, 2016, 21 (09)
  • [10] Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes
    Storey, Robert F.
    Gurbel, Paul A.
    ten Berg, Jurrien
    Bernaud, Corine
    Dangas, George D.
    Frenoux, Jean-Marie
    Gorog, Diana A.
    Hmissi, Abdel
    Kunadian, Vijay
    James, Stefan K.
    Tanguay, Jean-Francois
    Tran, Henry
    Trenk, Dietmar
    Ufer, Mike
    Van der Harst, Pim
    Van't Hof, Arnoud W. J.
    Angiolillo, Dominick J.
    EUROPEAN HEART JOURNAL, 2020, 41 (33) : 3132 - 3140
12